04:10 AM EDT, 06/12/2024 (MT Newswires) -- Evotec (EVO) said Wednesday it has made progress in its eight-year collaboration with Bristol Myers Squibb ( BMY ) on neurodegenerative diseases, triggering a payment of $20 million to Evotec.

The company did not disclose the nature of the milestone but said that a target-based plan to develop treatments has advanced into late pre-clinical development, contributing to the pipeline of products addressing neurodegenerative disorders.

Price: 4.4500, Change: -0.32, Percent Change: -6.71